GU Cancers 2018 | Systemic treatments for non-muscle invasive bladder cancer
Speaking from the 2018 Genitourinary Cancers Symposium in San Francisco, CA, Peter Black, MD, of the University of British Columbia, Vancouver, CA, outlines the development of systemic therapy for non-muscle invasive bladder cancer.
Transcript (edited for clarity)
Well it’s a very interesting time in immunotherapy and bladder cancer and this itself is sort of the next step of moving it further forward in the disease space. So right now it’s approved in second line metastatic and trials have been completed in first line metastatic and it’s just moving down the pipeline. So this is a paradigm shift, up until now we just give drugs into the bladder for non-muscle invasive disease so to give systemic therapy for non-muscle invasive disease is quite a change...
Well it’s a very interesting time in immunotherapy and bladder cancer and this itself is sort of the next step of moving it further forward in the disease space. So right now it’s approved in second line metastatic and trials have been completed in first line metastatic and it’s just moving down the pipeline. So this is a paradigm shift, up until now we just give drugs into the bladder for non-muscle invasive disease so to give systemic therapy for non-muscle invasive disease is quite a change. They appear to be safe and well tolerated, it could provide a very important alternative to cystectomy in these patients. I think moving forward is going to be really interesting to look at combinations; I think we can’t expect a higher proportion of patients to respond in the early disease setting as in the late disease setting, it’s not going to be 80/90 percent it’s still going to be 20 to 30 percent. So we need to improve upon that with biomarkers for selection and with combination therapies.
Read more...
